Black checkmark with a sparkle and a curved line underneath on a white background.
Company

RETRACTABLE TECHNOLOGIES INC

Ticker
RVP
Sector
Industry
Report date
November 16, 2026
Valye AI Score

100

Very high visibility
Recent developments
Recent developments summary

Recent news coverage highlights mixed quarterly earnings results with tariff and cost pressures impacting the company. Insider buying activity has been noted in prior years.

Recent developments:
  • RVP stock gained following Q2 2026 earnings despite declines in sales and unit volumes [N1].
  • The stock slipped after Q1 2026 earnings due to year-over-year sales decline [N2].
  • RVP stock plunged post Q4 2025 earnings despite revenue growth [N3][N4].
  • Stock rose after Q3 2025 earnings despite tariff and cost pressures [N5].
  • Insider buying reports have been published in prior years indicating management share purchases [N8].
Overview

Retractable Technologies, Inc. develops, manufactures, and markets safety medical products, predominantly syringes and needles with retractable safety features to protect healthcare workers and patients. Its key product lines include VanishPoint®, EasyPoint®, and Patient Safe® brands. The company has manufacturing operations in Little Elm, Texas, and sources products from China, where tariffs have significantly increased costs. It has expanded domestic manufacturing capacity funded partly by a U.S. government Technology Investment Agreement. The company is subject to FDA and international regulatory requirements and competes primarily on safety, product performance, and quality against larger competitors such as Becton, Dickinson and Company and Embecta Corp. The business is impacted by tariffs, regulatory compliance costs, and market acceptance of vaccinations. As of September 30, 2026, the company reported a net loss and maintains a strong liquidity position [S1][S2].

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Retractable Technologies, Inc. is a manufacturer of safety medical products, primarily syringes with retractable needles designed to reduce needlestick injuries. The company operates manufacturing facilities in Texas and sources products from China, facing significant tariffs on imports. It has expanded domestic manufacturing capacity with government funding. The company competes on safety and quality against larger competitors. Recent financials show a net loss and a strong liquidity position as of September 30, 2026. Recent news highlights mixed earnings results with tariff and cost pressures impacting operations [S1][S2][N1][N2][N3][N4][N5].

Scenarios for RVP

Bull case model:

The company benefits from patented safety features in its syringes and needles that address healthcare worker safety and medication efficiency. Its expanded domestic manufacturing capacity, supported by government funding, may help mitigate tariff impacts. The company maintains certifications and pursues regulatory approvals to support market access. Its products have established brand recognition and are used widely in healthcare settings. Insider buying activity suggests management confidence. These factors contribute to a resilient business model in a specialized medical device niche [S1][N8].

Bear case model:

The company faces significant challenges from high tariffs on imported products from China, increasing costs and complicating supply chain management. It competes against larger companies with greater resources and market share, which may limit growth opportunities. Regulatory compliance costs are substantial and may increase with evolving standards. Demand may be affected by public sentiment toward vaccinations and inventory levels of vaccination-related products. Recent financial results show net losses and declines in sales and unit volumes, indicating operational pressures [S1][N2][N3][N4][N5].

Moat:

The company's moat is based on its patented safety medical products with retractable needle technology designed to reduce needlestick injuries and medication waste. Its VanishPoint® syringes meet pharmaceutical low dead space criteria, providing a competitive advantage in medication efficiency. The company holds patents expiring between 2028 and 2032, with pending applications for further innovations. Its products are certified to stringent quality standards (ISO 13485:2016, MDSAP) and have established brand recognition in safety syringes. However, it faces competition from larger, better-resourced companies with greater market share. Tariffs on imported products and regulatory compliance costs also challenge its competitive position [S1].

Risks overview
Risks summary
Tariff and trade policy risks combined with competitive pressures and regulatory compliance costs represent the most significant risks to the company's business and financial performance.
Risks details:

• Tariff and Trade Policy Risks: The company faces high and fluctuating tariffs on products imported from China, including a 120% tariff on syringes and needles as of March 2026, which materially impact sourcing costs and business operations [S1].
• Competitive Risks: The company competes with larger, better-resourced firms such as Becton, Dickinson and Company and Embecta Corp., which may limit its ability to gain market share [S1].
• Regulatory Compliance Risks: The company is subject to stringent FDA and international regulations, with ongoing costs and risks related to compliance, approvals, and potential enforcement actions [S1].
• Market Demand Risks: Demand for the company's products may be affected by public acceptance of vaccinations and inventory levels of vaccination-related products, which are difficult to estimate [S1].
• Financial Performance Risks: Recent financial results show net losses and declines in sales and unit volumes, indicating operational and market challenges [S2][N2][N3].

FINAL FORECAST FOR RVP

Final take one line
Retractable Technologies exhibits very high visibility with detailed disclosures on its safety medical products business, regulatory environment, and tariff-related challenges.
Final take 12 to 24 month view

Business trends: The company faces ongoing tariff impacts on imports from China, shifts toward increased domestic manufacturing, and fluctuating demand influenced by vaccination trends.
Execution milestones: Expansion of domestic manufacturing capacity funded by government agreements, ongoing regulatory compliance efforts, and product development including FDA submissions.
Key risks: Tariff and trade policy uncertainties, competitive pressures from larger firms, regulatory compliance costs, and variability in market demand for vaccination-related products.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

100
LLM visibility overview
LLM Visibility known facts
  • Retractable Technologies, Inc. manufactures and markets safety medical products, predominantly syringes, for the healthcare industry, with manufacturing facilities in Little Elm, Texas and outsourced manufacturing in China [S1].
  • The company's principal products include injection devices marketed under the VanishPoint®, Patient Safe®, and EasyPoint® brands, featuring retractable needles designed to protect healthcare workers from needlestick injuries [S1].
  • VanishPoint® syringes meet pharmaceutical criteria for low dead space, reducing medication waste and sometimes allowing additional doses per vial [S1].
  • In 2025, syringes accounted for 65.1% of sales, EasyPoint® products 31.2%, and other products 3.7% [S1].
  • The company faces significant tariffs on products imported from China, including a 120% tariff on syringes and needles as of March 2026, impacting sourcing costs and business operations [S1].
  • Retractable Technologies has increased domestic manufacturing capacity, partly funded by a Technology Investment Agreement with the U.S. Department of Defense and BARDA, including an $81 million facility expansion [S1].
  • The company is subject to stringent FDA and international regulatory requirements, including ISO 13485:2016 and Medical Device Single Audit Program certifications, and is pursuing EU MDR certification [S1].
  • The company competes primarily on safety, product performance, and quality, with competitors including Becton, Dickinson and Company and Embecta Corp., which have greater market share and resources [S1].
  • As of September 30, 2026, the company had 201 employees, with a focus on retaining manufacturing workforce amid tariff-driven shifts to domestic production [S1].
  • Financial snapshot as of September 30, 2026: cash and equivalents of $1.89 million, current assets of $64.64 million, current liabilities of $14.23 million, net loss of $2.36 million, basic and diluted EPS of -$0.08, and a current ratio of 4.54 [S2].
  • The company reported recent quarterly earnings with mixed results: Q2 2026 earnings gains despite declines in sales and unit volumes, Q1 2026 sales decline year-over-year, and Q4 2025 revenue growth but stock price declines [N1][N2][N3][N4].
  • Tariffs and cost pressures have been noted as challenges in recent earnings periods [N5].
  • Insider buying activity has been reported in prior years, indicating management confidence [N8].
Sources
Sources - Context summary

Generated 2026-11-16

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-27 | 10-K
  • S2 | 2026-11-16 | 10-Q
Sources - News headlines
  • N1 | 2026-08-20 | www.nasdaq.com | RVP Stock Gains Post Q2 Earnings Despite Fall in Sales & Unit Volumes | https://www.nasdaq.com/articles/rvp-stock-gains-post-q2-earnings-despite-fall-sales-unit-volumes
  • N2 | 2026-05-21 | www.nasdaq.com | Retractable Stock Slips Post Q1 Earnings, Sales Decline Y/Y | https://www.nasdaq.com/articles/retractable-stock-slips-post-q1-earnings-sales-decline-y-y
  • N3 | 2026-04-01 | www.nasdaq.com | RVP Stock Plunges Post Q4 Earnings Despite Revenue Growth | https://www.nasdaq.com/articles/rvp-stock-plunges-post-q4-earnings-despite-revenue-growth-0
  • N4 | 2026-04-01 | www.nasdaq.com | RVP Stock Plunges Post Q4 Earnings Despite Revenue Growth | https://www.nasdaq.com/articles/rvp-stock-plunges-post-q4-earnings-despite-revenue-growth
  • N5 | 2025-11-20 | www.nasdaq.com | RVP Stock Rises Post Q3 Earnings Despite Tariff and Cost Pressures | https://www.nasdaq.com/articles/rvp-stock-rises-post-q3-earnings-despite-tariff-and-cost-pressures
  • N6 | 2025-08-21 | www.nasdaq.com | Retractable Technologies Stock Gains Following Q2 Earnings Growth | https://www.nasdaq.com/articles/retractable-technologies-stock-gains-following-q2-earnings-growth
  • N7 | 2025-06-19 | www.nasdaq.com | Zacks Initiates Coverage of Retractable Technologies With Underperform Recommendation | https://www.nasdaq.com/articles/zacks-initiates-coverage-retractable-technologies-underperform-recommendation
  • N8 | 2025-04-16 | www.nasdaq.com | Wednesday 4/16 Insider Buying Report: WDFC, RVP | https://www.nasdaq.com/articles/wednesday-4-16-insider-buying-report-wdfc-rvp
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine